SCHEMBL4634944

SCHEMBL4634944

CN(C(=O)c1sc2ccccc2c1OCC(=O)CCC(=O)O)C1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634474 0.87 ABCC1 (0.44) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4633943 0.86 ABCC1 (0.43) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4632940 0.83 ABCC1 (0.45) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4632921 0.82 CXCR2 (0.45) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4632936 0.80 ABCC1 (0.45) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4635005 0.79 CXCR2 (0.46) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4634941 0.79 ALDH1A1 (0.52) MEN1KMT2ASMN1; SMN2PTPN2PTPN1
SCHEMBL4635079 0.77 ABCC1 (0.44) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4633966 0.76 ABCC1 (0.43) ABCC1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4634461 0.76 ABCC1 (0.43) ABCC1MEN1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives GPR119, INSR, GLP1R ABCC1 9/4885MEN1 1735/4885KMT2A 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.